AstraZeneca and Daiichi's Breast Cancer Drug Meets Goal in Study

FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
TT
20

AstraZeneca and Daiichi's Breast Cancer Drug Meets Goal in Study

FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo

AstraZeneca said on Friday its experimental precision drug had slowed the progression of a common type of breast cancer in a late-stage trial, a boost for the company after its shares fell in July on results from a separate trial of the same drug for lung cancer.
The drug, datopotamab deruxtecan, which AstraZeneca is jointly developing with Japan's Daiichi Sankyo, is being closely watched by analysts and investors in part due to the promise of the class of drugs to which it belongs, known as antibody drug conjugates (ADC).
ADCs consist of tumor-seeking monoclonal antibodies that are combined with a cell-killing chemotherapy payload.
The trial data released on Friday showed the drug, abbreviated as Dato-DXd, demonstrated a statistically significant and clinically meaningful improvement in slowing the progression of a type of breast cancer in trial participants, compared to patients who received other treatments such as chemotherapy.
The trial focused on tumors that grow in response to the hormones estrogen or progesterone, which account for roughly two-thirds of breast cancer cases. The study participants' disease had spread to other parts of the body.
The British drugmaker also said that there was a "trend in improvement" in the other main goal of the study, "overall survival" of patients, but the data on that was not mature so the trial would continue as planned.
AstraZeneca shares rose 1.7% in early trading, to their highest level in more than five weeks.
AstraZeneca is simultaneously developing the drug for use in lung cancer, and while data from a separate late-stage trial released in July was positive, the market was concerned that the drug's benefits for use in lung cancer treatment might not as pronounced as hoped, leading shares to fall more than 6% on the day the data was released.
The company has not said when it will release detailed data from the lung cancer study.
Analysts see the positive results from the breast cancer trial as good for AstraZeneca, but the market is more focused on the results of a trial called MARIPOSA by Johnson & Johnson. It compares AstraZeneca’s blockbuster cancer drug Tagrisso alone with its own drug, Rybrevant, in combination with another medicine.
Those results are expected later this year.



Tourists Told to Heed Warnings after Etna Eruption 

Volcanic steam rises from Mount Etna, as seen from Milo, Italy, June 2, 2025. (Reuters)
Volcanic steam rises from Mount Etna, as seen from Milo, Italy, June 2, 2025. (Reuters)
TT
20

Tourists Told to Heed Warnings after Etna Eruption 

Volcanic steam rises from Mount Etna, as seen from Milo, Italy, June 2, 2025. (Reuters)
Volcanic steam rises from Mount Etna, as seen from Milo, Italy, June 2, 2025. (Reuters)

Tourists have been told to check for warnings before climbing towards the summit of Italy's Mount Etna after an eruption sent hikers scurrying for safety.

Video footage from Monday's eruption showed dozens of people hurrying down a path as a large plume of ash rose behind them from the volcano on the eastern side of the island of Sicily.

Salvo Cocina, the head of Sicily's Civil Protection Department, said dozens of hikers had ventured on to Etna despite a warning issued early on Monday morning after initial signs of increased activity on Europe's largest active volcano.

"There was a big explosion and a crater collapsed but luckily it fell into a deserted area," he told Reuters on Tuesday.

"It's very hard to block access, you can't fence it off," he added.

Cocina said those on the mountain on Monday, who had climbed to a height of some 2,700 meters, appeared to be properly equipped and he acknowledged the need to balance safety concerns with the desire of tourists to enjoy the views.

Nobody was injured in Monday's eruption and the alert for volcanic activity had been downgraded to the more standard "yellow" level on Tuesday.